101 related articles for article (PubMed ID: 21902681)
21. Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma.
Liu S; Ishikawa H; Li FJ; Ma Z; Otsuyama K; Asaoku H; Abroun S; Zheng X; Tsuyama N; Obata M; Kawano MM
Cancer Res; 2005 Mar; 65(6):2269-76. PubMed ID: 15781640
[TBL] [Abstract][Full Text] [Related]
22. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS
Br J Haematol; 2010 Aug; 150(3):313-25. PubMed ID: 20560971
[TBL] [Abstract][Full Text] [Related]
23. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
24. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
Mitsiades CS; Ocio EM; Pandiella A; Maiso P; Gajate C; Garayoa M; Vilanova D; Montero JC; Mitsiades N; McMullan CJ; Munshi NC; Hideshima T; Chauhan D; Aviles P; Otero G; Faircloth G; Mateos MV; Richardson PG; Mollinedo F; San-Miguel JF; Anderson KC
Cancer Res; 2008 Jul; 68(13):5216-25. PubMed ID: 18593922
[TBL] [Abstract][Full Text] [Related]
25. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
[TBL] [Abstract][Full Text] [Related]
26. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
[TBL] [Abstract][Full Text] [Related]
27. In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model.
Kanzawa F; Nishio K; Fukuoka K; Sunami T; Saijo N
Cancer Chemother Pharmacol; 1999; 43(5):353-63. PubMed ID: 10100589
[TBL] [Abstract][Full Text] [Related]
28. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
[TBL] [Abstract][Full Text] [Related]
29. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma.
Neri P; Tassone P; Shammas M; Yasui H; Schipani E; Batchu RB; Blotta S; Prabhala R; Catley L; Hamasaki M; Hideshima T; Chauhan D; Jacob GS; Picker D; Venuta S; Anderson KC; Munshi NC
Leukemia; 2007 Dec; 21(12):2519-26. PubMed ID: 17882285
[TBL] [Abstract][Full Text] [Related]
30. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
Corso A; Ferretti E; Lazzarino M
Hematology; 2005 Jun; 10(3):215-24. PubMed ID: 16019470
[TBL] [Abstract][Full Text] [Related]
31. [Spicamycin derivative].
Mizumura Y
Nihon Rinsho; 2006 Feb; 64(2):322-8. PubMed ID: 16454188
[TBL] [Abstract][Full Text] [Related]
32. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
[TBL] [Abstract][Full Text] [Related]
33. Reovirus as a viable therapeutic option for the treatment of multiple myeloma.
Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Gao H; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG
Clin Cancer Res; 2012 Sep; 18(18):4962-72. PubMed ID: 22761466
[TBL] [Abstract][Full Text] [Related]
34. Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathways.
Zheleznyak A; Mixdorf M; Marsala L; Prior J; Yang X; Cui G; Xu B; Fletcher S; Fontana F; Lanza G; Achilefu S
Theranostics; 2021; 11(16):7735-7754. PubMed ID: 34335961
[No Abstract] [Full Text] [Related]
35. The use of animal models in multiple myeloma.
Libouban H
Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
[TBL] [Abstract][Full Text] [Related]
36. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.
Yaccoby S; Pearse RN; Johnson CL; Barlogie B; Choi Y; Epstein J
Br J Haematol; 2002 Feb; 116(2):278-90. PubMed ID: 11841428
[TBL] [Abstract][Full Text] [Related]
37. KRN5500, a novel antitumor agent, induces apoptosis or cell differentiation in HL-60 cells.
Kawasaki K; Murakami T; Ita M; Sasaki K; Furukawa S
Cytometry; 2000 Mar; 39(3):211-6. PubMed ID: 10685078
[TBL] [Abstract][Full Text] [Related]
38. Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models.
Takahashi T; Honma Y; Miyake T; Adachi K; Takami S; Okada M; Kumanomidou S; Ikejiri F; Jo Y; Onishi C; Kawakami K; Moriyama I; Inoue M; Tanaka J; Suzumiya J
Int J Oncol; 2015 Apr; 46(4):1801-9. PubMed ID: 25672400
[TBL] [Abstract][Full Text] [Related]
39. ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.
Lath DL; Buckle CH; Evans HR; Fisher M; Down JM; Lawson MA; Chantry AD
PLoS One; 2018; 13(6):e0199517. PubMed ID: 29924867
[TBL] [Abstract][Full Text] [Related]
40. Antitumor efficacy of lidamycin against human multiple myeloma RPMI 8226 cells and the xenograft in nonobese diabetic/severe combined immunodeficiency mice.
Zhen Y; Shang B; Liu X; Lin Y; Zhen Y
J Cancer Res Ther; 2016; 12(1):182-7. PubMed ID: 27072234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
